Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.KAI Pharma recruits first patient in KAI-4169 Phase 1b trial
The study also is also expected to investigate the pharmacokinetics of KAI-4169 and its effect on parathyroid hormone (PTH) and serum calcium levels. The data from Phase 1
The study also is also expected to investigate the pharmacokinetics of KAI-4169 and its effect on parathyroid hormone (PTH) and serum calcium levels. The data from Phase 1
In the Phase 1 trial Stedivaze was administered to patients with mild to moderate asthma as a single IV bolus, the same as utilized in the ongoing Phase
Pfizer has initiated the recall as a precautionary step after finding a potential for a leak of the components contained in the wrap, which could cause skin injury
Lexiscan is an A2A adenosine receptor agonist approved for use as a pharmacologic stress agent in radionuclide MPI in patients unable to undergo adequate exercise stress. Lexiscan was
Ozurdex, a biodegradable implant, delivers an extended release of the corticosteroid dexamethasone through intravitreal injection with Allergan’s proprietary Novadur solid polymer delivery system. Ozurdex’s efficacy for the treatment
Tesetaxel is a new taxane that is administered by mouth as a capsule. The drug was developed with a goal of maintaining high antitumor activity while eliminating infusion
The merger brings $42m in assets to Biomagnetics, including land to expand, when necessary, to meet future production levels to fill anticipated market demands. Biomagnetics president Clayton Hardman
The Perrigo product is a proton pump inhibitor and antacid indicated for the treatment of frequent heartburn. Perrigo has also provided prior notice of this filing to Schering-Plough
OctoPlus provides formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide. In addition OctoPlus offers its clients drug delivery technologies for the development of
Novartis said that the CHMP recommendation will serve as the basis for the European Commission making its licensing decision of the Aflunov product. Based on the CHMP approval,